Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BAFNAPH.NS Stock Summary
Top 10 Correlated ETFs
BAFNAPH.NS
In the News
BAFNAPH.NS Financial details
Company Rating
Neutral
Market Cap
1.88B
Income
112.65M
Revenue
1.53B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
588
Optionable
No
Shortable
Yes
Earnings
22 May 2024
P/E
14.08
Forward P/E
-
PEG
1.18
P/S
1.52
P/B
2.94
P/C
-
P/FCF
-
Quick Ratio
1.1
Current Ratio
2.06
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.84
EPS next Y
-
EPS next Q
-
EPS this Y
116.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
21.62%
Revenue Q/Q
-30.08%
EPS Q/Q
-218.1%
-
-
-
-
SMA20
-11.24%
SMA50
-21.78%
SMA100
-8.14%
Inst Own
-
Inst Trans
-
ROA
13%
ROE
31%
ROC
0.2%
Gross Margin
32%
Oper. Margin
11%
Profit Margin
11%
Payout
-
Shs Outstand
23.66M
Shs Float
1.92M
-
-
-
-
Target Price
-
52W Range
77.05-124.45
52W High
-36.81%
52W Low
+1.75%
RSI
31
Rel Volume
2.63
Avg Volume
8.85K
Volume
23.23K
Perf Week
-1.94%
Perf Month
-13.71%
Perf Quarter
-12.94%
Perf Half Y
-6.22%
-
-
-
-
Beta
0.525
-
-
Volatility
0.92%, 4.44%
Prev Close
0%
Price
78.35
Change
2.82%
BAFNAPH.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 18.33 | 17.95 | 30.11 | 35.99 | 48.76 | |
Net income per share | -7.98 | -10.45 | 2.46 | 2.21 | 4.79 | |
Operating cash flow per share | -0.76 | -14.5 | -5.75 | 3.4 | 2.09 | |
Free cash flow per share | -0.9 | -15.11 | -8.33 | 0.21 | -1.38 | |
Cash per share | 0.06 | 3.46 | 0.32 | 0.01 | 3.3 | |
Book value per share | 8.06 | 21.61 | 24 | 26.58 | 31.05 | |
Tangible book value per share | 7.94 | 21.63 | 24 | 26.58 | 30.42 | |
Share holders equity per share | 8.06 | 21.61 | 24 | 26.58 | 31.05 | |
Interest debt per share | 20.37 | 0.22 | 6.71 | 4.04 | 10.55 | |
Market cap | 229.47M | 314.63M | 3.25B | 3B | 1.94B | |
Enterprise value | 690.35M | 262.95M | 3.4B | 3.09B | 2.09B | |
P/E ratio | -1.22 | -1.27 | 55.8 | 57.44 | 17.11 | |
Price to sales ratio | 0.53 | 0.74 | 4.57 | 3.52 | 1.68 | |
POCF ratio | -12.84 | -0.92 | -23.89 | 37.3 | 39.17 | |
PFCF ratio | -10.82 | -0.88 | -16.5 | 610.56 | -59.39 | |
P/B Ratio | 1.2 | 0.62 | 5.73 | 4.76 | 2.64 | |
PTB ratio | 1.2 | 0.62 | 5.73 | 4.76 | 2.64 | |
EV to sales | 1.59 | 0.62 | 4.78 | 3.62 | 1.81 | |
Enterprise value over EBITDA | -21.03 | 18.63 | 32.73 | 23.16 | 11.01 | |
EV to operating cash flow | -38.63 | -0.77 | -25 | 38.43 | 42.22 | |
EV to free cash flow | -32.56 | -0.74 | -17.27 | 628.95 | -64.02 | |
Earnings yield | -0.82 | -0.79 | 0.02 | 0.02 | 0.06 | |
Free cash flow yield | -0.09 | -1.14 | -0.06 | 0 | -0.02 | |
Debt to equity | 2.43 | 0.01 | 0.28 | 0.14 | 0.31 | |
Debt to assets | 0.39 | 0.01 | 0.18 | 0.1 | 0.18 | |
Net debt to EBITDA | -14.04 | -3.66 | 1.45 | 0.68 | 0.8 | |
Current ratio | 0.68 | 2.11 | 2.04 | 3.14 | 1.88 | |
Interest coverage | -8.27 | -1.97K | 69.36 | 12.67 | 5.78 | |
Income quality | 0.1 | 18.22 | -2.34 | 1.1 | 0.42 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.01 | 0.03 | 0.01 | 0.02 | 0.01 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.01 | |
Capex to operating cash flow | 0.19 | 0.04 | 0.45 | -0.94 | -1.66 | |
Capex to revenue | -0.01 | -0.03 | -0.09 | -0.09 | -0.07 | |
Capex to depreciation | -0.1 | -0.44 | -1.36 | -1.37 | -1.54 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 38.03 | 71.29 | 36.47 | 36.32 | 57.87 | |
ROIC | -0.26 | -0.5 | 0.09 | 0.08 | 0.12 | |
Return on tangible assets | -0.16 | -0.35 | 0.07 | 0.06 | 0.09 | |
Graham Net | -28.17 | 1.63 | -5.61 | -2.54 | -2.52 | |
Working capital | -223.52M | 189.96M | 253.6M | 350.09M | 408.35M | |
Tangible asset value | 188.16M | 511.6M | 567.71M | 628.8M | 719.55M | |
Net current asset value | -521.51M | 159.79M | 199.73M | 240.35M | 311.83M | |
Invested capital | 2.43 | 0.01 | 0.28 | 0.14 | 0.31 | |
Average receivables | 381.91M | 261.95M | 120.36M | 127.74M | 283.05M | |
Average payables | 340.84M | 260.5M | 116.17M | 115.48M | 204.33M | |
Average inventory | 99.78M | 103.47M | 134.28M | 178.62M | 212.5M | |
Days sales outstanding | 327.74 | 115.65 | 54.41 | 64.02 | 131.88 | |
Days payables outstanding | 417.68 | 169.39 | 85.85 | 88.29 | 135.63 | |
Days of inventory on hand | 98.01 | 154.13 | 124.01 | 144.34 | 105.88 | |
Receivables turnover | 1.11 | 3.16 | 6.71 | 5.7 | 2.77 | |
Payables turnover | 0.87 | 2.15 | 4.25 | 4.13 | 2.69 | |
Inventory turnover | 3.72 | 2.37 | 2.94 | 2.53 | 3.45 | |
ROE | -0.99 | -0.48 | 0.1 | 0.08 | 0.15 | |
Capex per share | -0.14 | -0.6 | -2.58 | -3.19 | -3.47 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 14.46 | 19.19 | 17.73 | 17.2 | 12.02 | |
Net income per share | 1.27 | 2.44 | 2.68 | 1.05 | -1.24 | |
Operating cash flow per share | 1.18 | 1.39 | 1.03 | 1.05 | 1.07 | |
Free cash flow per share | 1.18 | 1.39 | 1.03 | 1.05 | 1.07 | |
Cash per share | 0 | 3.55 | 0 | 3.32 | 0 | |
Book value per share | 0 | 33.37 | 0 | 34.82 | 0 | |
Tangible book value per share | 0 | 32.69 | 0 | 33.83 | 0 | |
Share holders equity per share | 0 | 33.37 | 0 | 34.82 | 0 | |
Interest debt per share | 0.24 | 10.74 | 0.25 | 7.2 | 0.24 | |
Market cap | 2.38B | 1.8B | 2.4B | 1.98B | 2.2B | |
Enterprise value | 2.38B | 1.96B | 2.4B | 2.06B | 2.2B | |
P/E ratio | 19.89 | 8.4 | 9.45 | 19.89 | -18.69 | |
Price to sales ratio | 6.97 | 4.27 | 5.72 | 4.86 | 7.74 | |
POCF ratio | 85.22 | 59.16 | 98.97 | 79.63 | 86.56 | |
PFCF ratio | 85.22 | 59.16 | 98.97 | 79.63 | 86.56 | |
P/B Ratio | 0 | 2.46 | 0 | 2.4 | 0 | |
PTB ratio | 0 | 2.46 | 0 | 2.4 | 0 | |
EV to sales | 6.97 | 4.63 | 5.72 | 5.07 | 7.74 | |
Enterprise value over EBITDA | 48.01 | 24.82 | 29.4 | 49.57 | -200.75 | |
EV to operating cash flow | 85.22 | 64.12 | 98.97 | 83.14 | 86.56 | |
EV to free cash flow | 85.22 | 64.12 | 98.97 | 83.14 | 86.56 | |
Earnings yield | 0.01 | 0.03 | 0.03 | 0.01 | -0.01 | |
Free cash flow yield | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
Debt to equity | 0 | 0.31 | 0 | 0.2 | 0 | |
Debt to assets | 0 | 0.18 | 0 | 0.12 | 0 | |
Net debt to EBITDA | 0 | 1.92 | 0 | 2.1 | 0 | |
Current ratio | 0 | 1.88 | 0 | 2.06 | 0 | |
Interest coverage | 6.25 | 9.02 | 8.46 | 6.67 | -4.11 | |
Income quality | 0.93 | 0.57 | 0.38 | 1 | -0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.04 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0.04 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.01 | 0 | 0.02 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 42.81 | 0 | 28.68 | 0 | |
ROIC | 0 | 0.06 | 0 | 0.03 | 0 | |
Return on tangible assets | 0 | 0.04 | 0 | 0.02 | 0 | |
Graham Net | 0 | -2.7 | 0 | 0.2 | 0 | |
Working capital | 0 | 408.35M | 78.1M | 467.23M | 0 | |
Tangible asset value | 0 | 719.55M | 0 | 800.3M | 0 | |
Net current asset value | 0 | 311.83M | 78.1M | 384.43M | 0 | |
Invested capital | 0 | 0.31 | 0 | 0.2 | 0 | |
Average receivables | 105.16M | 208.39M | 208.39M | 202.94M | 202.94M | |
Average payables | 82.74M | 142.3M | 142.3M | 150.93M | 150.93M | |
Average inventory | 107.89M | 111.1M | 111.1M | 146.81M | 146.81M | |
Days sales outstanding | 0 | 88.79 | 0 | 89.8 | 0 | |
Days payables outstanding | 0 | 92 | 0 | 94.35 | 0 | |
Days of inventory on hand | 0 | 71.82 | 0 | 91.78 | 0 | |
Receivables turnover | 0 | 1.01 | 0 | 1 | 0 | |
Payables turnover | 0 | 0.98 | 0 | 0.95 | 0 | |
Inventory turnover | 0 | 1.25 | 0 | 0.98 | 0 | |
ROE | 0 | 0.07 | 0 | 0.03 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BAFNAPH.NS Frequently Asked Questions
What is Bafna Pharmaceuticals Limited stock symbol ?
Bafna Pharmaceuticals Limited is a IN stock and trading under the symbol BAFNAPH.NS
What is Bafna Pharmaceuticals Limited stock quote today ?
Bafna Pharmaceuticals Limited stock price is $78.35 today.
Is Bafna Pharmaceuticals Limited stock public?
Yes, Bafna Pharmaceuticals Limited is a publicly traded company.